A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar

Exclusion Criteria

• •For subjects with hepatic impairment: evidence of progressive liver disease within the last 4 weeks, or biliary liver cirrhosis or other causes of hepatic impairment not related to parenchymal disorder and/or disease
• •For healthy volunteers: positive test for hepatitis B or C, alcohol intake of more than 14 units per week, or history of clinically significant alcohol or drug abuse
• •Acute infection or current malignancy requiring treatment
• •History of clinically significant allergic disease or drug hypersensitivity
• •Positive test for HIV-1 or HIV-2 at screening
• •Participation in a clinical study with an investigational drug or new chemical entity within 2 months prior to screening
• •Females who are pregnant or lactating